Choice of intrathecal drug in the treatment of neuropathic pain – new research and opinion

References

• Hurley RW, Adams MCB, Benzon HT. Neuropathic pain : treatment guidelines and updates. Curr Opin Anesth. 2013;26(5):580–587.
   PubMed Web of Science ®Google Scholar
• Bogduk N, Merskey H. Part III: pain terms, A current list with definitions and notes on usage”, classification of chronic pain [Internet]. Second. Seattle: IASP Press; 1994. p. 209–214. Available from: https://www.iasp-pain.org/PublicationsNews/Content.aspx?ItemNumber=1957&navItemNumber=677.
   Google Scholar
• Beal B, Wallace M. An overview of pharmacologic management of chronic pain. Med Clin N Am. 2016;100:65–79.
   PubMed Web of Science ®Google Scholar
• Wiffen P, Derry S, Bell R, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;6:10–13.
   Google Scholar
• Loeser D, Treede R, Turk DC, et al. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain. 2015;154(11):2249–2261.
   Web of Science ®Google Scholar
• Duarte R, Lambe T, Raphael J, et al. Intrathecal drug delivery systems for the management of chronic noncancer pain: a systematic review of economic evaluations. Pain Pract. 2018;18:666–686.
   PubMed Web of Science ®Google Scholar
• Costigan M, Scholz J, Woolf C. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci. 2009;32:1–32.
   PubMed Web of Science ®Google Scholar
• Treede R, Cohen M, Quintner J, et al. The international association for the study of pain definition of pain : as valid in 2018 as in 1979, but in need of regularly updated footnotes. Pain Rep. 2018;3:3–5.
   Google Scholar
• Deer TR, Pope JE, Hayek SM, et al. The polyanalgesic consensus conference (PACC): recommendations on intrathecal drug infusion systems best practices and guidelines. Neuromodulation. 2016;20:96–132.
   Web of Science ®Google Scholar
• US FDA. Analgesic indications: developing drug and biological products [Internet]. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER); 2014 [cited 2019 Aug 19]. p. 10. Available from: https://www.fda.gov/media/88133/download.
   Google Scholar
• Deer TR, Pope JE, Hayek SM, et al. The polyanalgesic consensus conference (PACC): recommendations for intrathecal drug delivery: guidance for improving safety and mitigating risks. Neuromodulation. 2016;20:155–176.
   Web of Science ®Google Scholar
• Hayek SM, Hanes MC. Intrathecal therapy for chronic pain: current trends and future needs. Curr Pain Headache Rep. 2014;18:388.
   PubMed Web of Science ®Google Scholar
• Campos LW, Pope JE. Pharmacology of Intrathecal Therapy [Internet]. In: Neuromodulation. Second. Philadelphia, PA: Elsevier Ltd; 2019. p. 819–828. 10.1016/B978-0-12-805353-9.00066-8
   Google Scholar
• US FDA. Infumorph FDA label; 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/018565s022lbl_Infumorph.pdf. cited 2019 Aug 19
   Google Scholar
• US FDA. Prialt (Ziconotide Intrathecal Infusion) drug approval package [Internet]; 2005 [cited 2019 Aug 19]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/21-060_Prialt.cfm
   Google Scholar
• US FDA. Use caution with implanted pumps for intrathecal administration of medicines for pain management: FDA safety communication; 2018 [cited 2019 Aug 19]. Available from: https://www.fda.gov/medical-devices/safety-communications/use-caution-implanted-pumps-intrathecal-administration-medicines-pain-management-fda-safety.
   Google Scholar
• Deer T, Krames E, Hassenbusch S, et al. Management of intrathecal catheter-tip inflammatory masses: an updated 2007 consensus statement from an expert panel. Neuromodulation. 2008;11:77–91.
   PubMed Web of Science ®Google Scholar
• Boswell M, Iacono R, Guthkelch A. Sites of action of sub- arachnoid lidocaine and tetracaine: observations with evoked potential monitoring during spinal cord stimulator implantation. Reg Anesth. 1992;17:37–42.
   PubMedGoogle Scholar
• Mironer Y, Haasis J, Chapple I, et al. Efficacy and safety of intrathecal opioids/bupivacaine mixture in chronic nonmalignant pain: a double blind, randomized, crossover multicenter study by the national forum of independent pain clinicians (NFIPC). Neuromodulation. 2002;5:208–213.
   PubMed Web of Science ®Google Scholar
• Feng X, Zhang F, Dong R, et al. Intrathecal administration of clonidine attenuates spinal neuroimmune activation in a rat model of neuropathic pain with existing hyperalgesia. Eur J Pharmacol. 2009;614:38–43.
   PubMed Web of Science ®Google Scholar
• Bevacqua B, Fattouh M, Backonja M. Depression, night terrors, and insomnia associated with long-term intrathecal clonidine therapy. Pain Pract. 2007;7:36–38.
   PubMedGoogle Scholar
• Deer T, Rauck RL, Kim P, et al. Effectiveness and safety of intrathecal ziconotide : interim analysis of the patient registry of intrathecal ziconotide management. Pain Pract. 2018;18(2):230–238.
   PubMed Web of Science ®Google Scholar
• Deer TR, Pope JE, Hanes MC, et al. Intrathecal therapy for chronic pain : a review of morphine and ziconotide as firstline options. Pain Med. 2018;20(4):1–15.
   Web of Science ®Google Scholar
• Jamison DE, Cohen SP, Rosenow J. Implanted drug delivery systems for control of chronic pain [Internet]. In: Essentials of pain medicine. Fourth. Elsevier; 2018. p. 693–702.e2. DOI: 10.1016/B978-0-323-40196-8.00076-0
   Google Scholar
• Ghobadifar MA, Pourghashdar F, Akbarzadeh A, et al. Combined use of intrathecal opioids and dexmedetomidine in the management of neuropathic pain. Korean J Pain. 2015;28(2):156–157.
   PubMed Web of Science ®Google Scholar
• Işgüzar O, Bariş S, Bozkurt A, et al. Evaluation of antinociceptive and neurotoxic effects of intrathecal dexmedetomidine in rats. Balk Med J. 2012;29:354–357.
   PubMed Web of Science ®Google Scholar
• Kabalak A, Ekmekçioğlu E, Ceylan A, et al. The synergistic antinociceptive interactions of morphine and dexmedetomidine in rats with nerve-ligation injury. Hippokratia. 2013;17:326–331.
   PubMed Web of Science ®Google Scholar
• Tangherlini G, D V K, Schepmann D, et al. Development of novel quinoxaline-based κ‑opioid receptor agonists for the treatment of neuroin fl ammation. J Med Chem. 2018;62(2):893–907.
   Web of Science ®Google Scholar
• Stein C, Lang LJ. Peripheral mechanisms of opioid analgesia. Curr Opin Pharmacol. 2009;9:3–8.
   PubMed Web of Science ®Google Scholar
• Coull J, Beggs S, Boudreau D, et al. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature. 2005;438:1017–1021.
   PubMed Web of Science ®Google Scholar
• Grace PM, Hutchinson MR, Maier SF, et al. Pathological pain and the neuroimmune interface. Nat Rev Immunol. 2014;14(4):217-231.
   Web of Science ®Google Scholar
• Luo X, Fitzsimmons B, Mohan A, et al. Intrathecal administration of antisense oligonucleotide against p38α but not p38β MAP kinase isoform reduces neuropathic and postoperative pain and TLR4-induced pain in male mice. Brain Behav Immun. 2018;72:34–44.
   PubMed Web of Science ®Google Scholar
• Chen G, Luo X, Qadri M, et al. Sex-dependent glial signaling in pathological pain: distinct roles of spinal microglia and astrocytes. Neurosci Bull. 2017;34(1):98–108.
   PubMed Web of Science ®Google Scholar
• Dalgarno R, Leduc-Pessah H, Pilapil A, et al. Intrathecal delivery of a palmitoylated peptide targeting Y 382-384 within the P2X7 receptor alleviates neuropathic pain. Mol Pain. 2018;14:1–10.
   Web of Science ®Google Scholar
• Park J, Park HJ. Botulinum toxin for the treatment of neuropathic pain. Toxins (Basel). 2017;9:260-275.
   Web of Science ®Google Scholar
• Brown DC, Agnello K. Intrathecal substance P-saporin in the dog: efficacy in bone cancer pain. Anesthesiology. 2013;119:1178–1185.
   PubMed Web of Science ®Google Scholar
• Leese C, Certo M, Echeverria-altuna I, et al. Selective neuronal silencing using synthetic botulinum molecules alleviates chronic pain in mice. Sci Transl Med. 2018;450(10):1–37.
   Google Scholar
• Latorre R, Brauchi S, Orta G, et al. ThermoTRP channels as modular proteins with allosteric gating. Cell Calcium. 2007;42:427–438.
   PubMed Web of Science ®Google Scholar
• Kissin I, Davison N, Bradley EJ. Perineural resiniferatoxin prevents hyperalgesia in a rat model of postoperative pain. Anesth Analg. 2005;100:74–80.
   Web of Science ®Google Scholar
• Haanpää M, Treede R. Capsaicin for neuropathic pain: linking traditional medicine and molecular biology. Eur Neurol. 2012;68:264–275.
   PubMed Web of Science ®Google Scholar
• Szallasi U, Blumber P. Resiniferatoxin and its analogs provide novel insights into the pharmacology of the vanilloid (capsaicin) receptor. Life Sci. 1990;47:399–408.
   Web of Science ®Google Scholar
• Iadarola M, Mannes A. The vanilloid agonist resiniferatoxin for interventional‑ based pain control. Top Med Chem. 2011;11:2171–2179.
   PubMed Web of Science ®Google Scholar
• Parisi JR, Laura A, De Andrade M, et al. Antiallodynic effect of intrathecal resiniferatoxin on neuropathic pain model of chronic constriction injury. Acta Neurobiol Exp. 2017;77:317–322.
   PubMed Web of Science ®Google Scholar
• Deer TR, Prager J, Levy R, et al. Polyanalgesic consensus conference 2012 : recommendations for the management of pain by intrathecal (intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation. 2012;15:436–466.
   PubMed Web of Science ®Google Scholar